Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Galderma Laboratories, L.P. |
---|---|
Information provided by: | Galderma Laboratories, L.P. |
ClinicalTrials.gov Identifier: | NCT00469183 |
Evaluate atrophogenic potential of long-term use of Tri-Luma Cream on facial Melasma through biopsy examination.
Condition | Intervention | Phase |
---|---|---|
Melasma |
Drug: Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05% |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | An Assessment of the Atrophogenic Potential of Triple Combination Cream Using Histology Measures in the Treatment of Moderate to Severe Melasma |
Enrollment: | 70 |
Study Start Date: | May 2006 |
Study Completion Date: | April 2007 |
Primary Completion Date: | April 2007 (Final data collection date for primary outcome measure) |
Same as above.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Vitiligo and Pigmentation Institute of Southern California | |
Los Angeles, California, United States, 90036 | |
United States, Texas | |
University of Texas Southwestern Medical Center of Dallas | |
Dallas, Texas, United States, 75390 |
Study Director: | Ronald W Gottschalk, MD | Galderma Laboratories, L.P. |
Responsible Party: | Galderma laboratories, L.P. ( Ronald W. Gottschalk, MD / Medical Director ) |
Study ID Numbers: | US10010 |
Study First Received: | May 2, 2007 |
Last Updated: | March 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00469183 |
Health Authority: | United States: Institutional Review Board |
Hyperpigmentation Skin Diseases Fluocinolone Acetonide Pigmentation Disorders |
Hydroquinone Tretinoin Melanosis |
Anti-Inflammatory Agents Therapeutic Uses Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists |
Hormones Glucocorticoids Pharmacologic Actions |